Catalyst Biosciences, Inc. Common Stock, also called Catalyst Biosciences, is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address serious medical conditions. Read More Its pipeline includes hemostasis such as Factor VIIa marzeptacog alfa, Factor IX dalcinonacog alfa, and Factor Xa; and anti-complement. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.